NCT00104234

Study of rhASB in Patients With Mucopolysaccharidosis VI

A Multicenter, Multinational Open-Label Extension Study of Recombinant Human N-acetylgalactosamine 4-sulfatase (rhASB) in Patients With Mucopolysaccharidosis VI

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 39 (actual)
• Sponsor: BioMarin Pharmaceutical · Industry
• Sex: All
• Age: 7 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the long-term efficacy and safety of rhASB treatment in patients with Mucopolysaccharidosis VI.

Conditions

• Mucopolysaccharidosis VI

Interventions

Type	Name	Description
DRUG	N-acetylgalactosamine 4-sulfatase
DRUG	Placebo/rhASB

Timeline

• Start date: 2004-02-01
• Primary completion: 2006-10-01
• Completion: 2006-10-01
• First posted: 2005-02-25
• Last updated: 2010-02-02
• Results posted: 2009-03-06

Locations

1 site across 1 country: United States